Xiaflex - Drug Monograph

Introduction

Xiaflex (collagenase clostridium histolyticum) is a proteolytic enzyme complex used for the nonsurgical treatment of fibrotic conditions. It is the first and only FDA-approved pharmacologic agent for Peyronie's disease and Dupuytren's contracture, offering a minimally invasive alternative to surgery. Its clinical relevance lies in its ability to enzymatically disrupt collagen deposits, thereby reducing contracture and curvature without the need for operative intervention.

Drug Class and Overview

Xiaflex is a biologic enzyme classified as a collagenase. It is derived from the bacterium Clostridium histolyticum and contains two distinct collagenase isoforms (AUX-I and AUX-II) that work synergistically. Unlike anti-inflammatory or anti-fibrotic small molecules, Xiaflex directly degrades collagen. It has no direct pharmacologic relatives in clinical use; however, it is conceptually similar to other enzymatic debriding agents (e.g., papain-urea) but is far more specific for collagen types I and III, which are predominant in the affected tissues.

Mechanism of Action

Xiaflex exerts its effect through the enzymatic cleavage of collagen. The two collagenase isoforms (AUX-I and AUX-II) bind to and hydrolyze collagen in its triple-helical conformation at neutral pH. This breaks down the insoluble collagen fibers that form the pathologic cords in Dupuytren's contracture and the fibrotic plaques in Peyronie's disease. The degradation of these collagen deposits leads to cord rupture or plaque softening, allowing for manual manipulation (e.g., finger extension or penile modeling) to restore functional anatomy. The body's endogenous proteases subsequently clear the digested collagen fragments.

Indications

• Dupuytren's Contracture: Treatment of adult patients with a palpable cord of Dupuytren's contracture.
• Peyronie's Disease: Treatment of adult men with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

Dosage and Administration

Dupuytren's Contracture:

• Dose: 0.58 mg (0.25 mL of reconstituted solution) injected directly into the palpable cord.
• Administration: Up to 3 injections per cord at approximately 4-week intervals. Each injection is followed 24–72 hours later by a finger extension procedure to facilitate cord rupture.
• Maximum: No more than 3 injections per cord; only one cord treated per visit.

Peyronie's Disease:

• Dose: 0.58 mg (0.25 mL) injected directly into the Peyronie's plaque.
• Administration: Up to 8 injections total, with cycles of 2 injections separated by approximately 6 weeks. After the second injection in each cycle, the clinician performs penile modeling.
• Maximum: 8 injections over the course of therapy.

Renal/Hepatic Impairment: No formal pharmacokinetic studies have been conducted; no dose adjustment is recommended based on available data.

Special Populations:

• Pediatric: Safety and efficacy have not been established.
• Geriatric: No specific dose adjustments required; clinical trials included older adults.
• Pregnancy: Not indicated in women; no adequate human data. Animal studies suggest risk based on mechanism of action (teratogenic potential due to collagenase activity).

Pharmacokinetics

• Absorption: Xiaflex is administered locally via intralesional injection. Systemic absorption is minimal and not reliably measurable.
• Distribution: Following injection, the enzyme is largely confined to the injection site and surrounding tissue. Systemic distribution is negligible.
• Metabolism: The collagenase is a protein and is expected to be degraded by endogenous proteases into small peptides and amino acids. No CYP-mediated metabolism is involved.
• Elimination: The breakdown products are eliminated via normal protein catabolism pathways. No renal or biliary excretion of the intact enzyme occurs.
• Half-life: The systemic half-life is not well characterized due to undetectable systemic levels; local tissue half-life is estimated to be several hours to days.

Contraindications

• Hypersensitivity: Known allergy to collagenase clostridium histolyticum or any of its excipients (e.g., sucrose, tris hydrochloride).
• Coagulation Abnormalities: Patients with significant bleeding disorders or those currently receiving anticoagulant therapy (except low-dose aspirin) within 7 days prior to injection.
• Peyronie's Disease with Ventral Curvature: Treatment is contraindicated in men with ventral curvature or plaques that involve the urethra, due to risk of urethral injury.

Warnings and Precautions

• Corporal Rupture (Peyronie's Disease): Serious penile fracture or corporal rupture can occur, requiring surgical repair. Patients must be counseled to seek immediate medical attention for sudden loss of erection, severe pain, or swelling.
• Tendon Rupture (Dupuytren's Contracture): Injection into the flexor tendons can cause tendon rupture, which may require surgical intervention. Careful injection technique and avoidance of injecting into the tendon sheath are critical.
• Hypersensitivity Reactions: Severe anaphylactic reactions, including airway compromise, have been reported. Observe patients for at least 30 minutes post-injection.
• Nerve Injury: In Dupuytren's treatment, transient or permanent nerve damage has been reported, particularly in the digits.
• Bleeding Risk: Local ecchymosis and hematoma are common; use with caution in patients with coagulopathies.

Drug Interactions

• Anticoagulants (e.g., warfarin, heparin, direct oral anticoagulants): Concomitant use increases the risk of bleeding at the injection site. Xiaflex should not be administered within 7 days of anticoagulant use.
• Antiplatelet Agents (e.g., clopidogrel, prasugrel): Increased bleeding risk; caution is advised. Low-dose aspirin (≤150 mg/day) is generally permitted.
• Tetracyclines (e.g., minocycline, doxycycline): These agents inhibit matrix metalloproteinases and may theoretically reduce the efficacy of collagenase; however, clinical significance is unknown. Use with caution.

Adverse Effects

Common (≥5%):

• Injection site pain, edema, swelling, and ecchymosis.
• Pruritus and skin laceration (Dupuytren's).
• Penile hematoma, pain, and swelling (Peyronie's).
• Blood in urine (hematuria) in Peyronie's patients.

Serious/Rare:

• Anaphylaxis and severe hypersensitivity reactions.
• Tendon rupture (Dupuytren's).
• Corporal rupture/penile fracture (Peyronie's).
• Nerve injury (transient or permanent).
• Complex regional pain syndrome (rare).

Monitoring Parameters

• Immediate Post-Injection: Observe for signs of hypersensitivity for at least 30 minutes.
• Dupuytren's: Assess finger extension and neurovascular status at each follow-up visit (typically 1–4 weeks post-injection).
• Peyronie's: Monitor penile curvature and plaque characteristics before each cycle; assess for signs of corporal rupture (sudden pain, swelling, loss of erection).
• General: Monitor for excessive bleeding, ecchymosis, or signs of infection at the injection site.

Patient Education

• Purpose: Explain that Xiaflex is an enzyme that breaks down collagen to reduce contracture or curvature, and that multiple injections may be needed.
• Procedure: The injection is given directly into the cord or plaque; a follow-up manipulation (finger extension or penile modeling) is required 1–3 days later.
• Side Effects: Expect swelling, bruising, and pain at the injection site. Report severe pain, sudden loss of erection, or inability to move a finger immediately.
• Bleeding Precautions: Avoid anticoagulants and antiplatelet agents (except low-dose aspirin) for at least 7 days before injection.
• Activity: Avoid strenuous activity involving the treated hand or sexual activity for a period recommended by the clinician (typically 2–4 weeks).

Clinical Pearls

1. Mechanism Matters: Xiaflex is a direct collagenase, not an anti-inflammatory; its efficacy depends on physical disruption of collagen, not on modulating fibrosis pathways.
2. Injection Technique is Critical: For Dupuytren's, the needle must be placed within the cord, not the tendon; for Peyronie's, avoid the dorsal neurovascular bundle and urethra.
3. Timing of Manipulation: The finger extension or penile modeling procedure is essential for clinical benefit and should be performed 24–72 hours after injection.
4. Bleeding Risk: Always confirm anticoagulant status before injection; even a single dose of warfarin or DOAC within 7 days is a contraindication.
5. Surgical Backup: Be prepared for rare but serious complications like tendon or corporal rupture; patients should have a clear plan for emergency evaluation.
6. Realistic Expectations: In Peyronie's disease, Xiaflex reduces curvature by an average of 30–40%, but it does not restore normal erectile function or plaque resolution.

References

1. Endo Pharmaceuticals Inc. Xiaflex (collagenase clostridium histolyticum) prescribing information. Malvern, PA; 2021.
2. American Urological Association (AUA). Peyronie's Disease: AUA Guideline. 2015.
3. American Society for Surgery of the Hand (ASSH). Dupuytren's Contracture: Clinical Practice Guidelines. 2018.
4. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009;361(10):968-979.
5. Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy and safety of collagenase clostridium histolyticum for Peyronie's disease. J Urol. 2013;190(1):199-207.
6. Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 15th ed. McGraw-Hill Education; 2020.
7. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill Education; 2018.
8. Lexicomp Online. Collagenase Clostridium Histolyticum: Drug Information. Wolters Kluwer; 2023.